KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

被引:37
作者
Heward, James [1 ]
Konali, Lola [1 ]
D'Avola, Annalisa [2 ]
Close, Karina [1 ]
Yeomans, Alison [2 ]
Philpott, Martin [3 ]
Dunford, James [3 ]
Rahim, Tahrima [1 ]
Al Seraihi, Ahad F. [1 ]
Wang, Jun [1 ]
Korfi, Koorosh [1 ]
Araf, Shamzah [1 ]
Iqbal, Sameena [1 ]
Bewicke-Copley, Findlay [1 ]
Kumar, Emil [1 ]
Barisic, Darko [4 ]
Calaminici, Maria [1 ]
Clear, Andrew [1 ]
Gribben, John [1 ]
Johnson, Peter [2 ]
Neve, Richard [5 ]
Cutillas, Pedro [1 ]
Okosun, Jessica [1 ]
Oppermann, Udo [3 ]
Melnick, Ari [4 ]
Packham, Graham [2 ]
Fitzgibbon, Jude [1 ]
机构
[1] Queen Mary Univ London, Barts Canc Inst, Haematooncol, London, England
[2] Univ Southampton, Southampton Gen Hosp, Canc Res UK Ctr, Canc Sci,Fac Med, Southampton, Hants, England
[3] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[4] Weill Cornell Med, Dept Med, New York, NY USA
[5] Gilead Sci, Foster City, CA USA
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
SELECTIVE-INHIBITION; EZH2; MUTATIONS; CELL; GENE; EXPRESSION; GENOME; CANCER; FAMILY; INACTIVATION; DEMETHYLASES;
D O I
10.1182/blood.2020008743
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Loss-of-function mutations in KMT2D are a striking feature of germinal center (GC) lymphomas, resulting in decreased histone 3 lysine 4 (H3K4) methylation and altered gene expression. We hypothesized that inhibition of the KDM5 family, which demethylates H3K4me3/me2, would reestablish H3K4 methylation and restore the expression of genes repressed on loss of KMT2D. KDM5 inhibition increased H3K4me3 levels and caused an antiproliferative response in vitro, which was markedly greater in both endogenous and gene-edited KMT2D mutant diffuse large B-cell lymphoma cell lines, whereas tumor growth was inhibited in KMT2D mutant xenografts in vivo. KDM5 inhibition reactivated both KMT2D-dependent and -independent genes, resulting in diminished B-cell signaling and altered expression of B-cell lymphoma 2 (BCL2) family members, including BCL2 itself. KDM5 inhibition may offer an effective therapeutic strategy for ameliorating KMT2D loss-of-function mutations in GC lymphomas.
引用
收藏
页码:370 / 381
页数:12
相关论文
共 59 条
[1]   Epigenetic dysregulation in follicular lymphoma [J].
Araf, Shamzah ;
Okosun, Jessica ;
Koniali, Lola ;
Fitzgibbon, Jude ;
Heward, James .
EPIGENOMICS, 2016, 8 (01) :77-84
[2]   EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation [J].
Beguelin, Wendy ;
Popovic, Relja ;
Teater, Matt ;
Jiang, Yanwen ;
Bunting, Karen L. ;
Rosen, Monica ;
Shen, Hao ;
Yang, Shao Ning ;
Wang, Ling ;
Ezponda, Teresa ;
Martinez-Garcia, Eva ;
Zhang, Haikuo ;
Zheng, Yupeng ;
Verma, Sharad K. ;
McCabe, Michael T. ;
Ott, Heidi M. ;
Van Aller, Glenn S. ;
Kruger, Ryan G. ;
Liu, Yan ;
McHugh, Charles F. ;
Scott, David W. ;
Chung, Young Rock ;
Kelleher, Neil ;
Shaknovich, Rita ;
Creasy, Caretha L. ;
Gascoyne, Randy D. ;
Wong, Kwok-Kin ;
Cerchietti, Leandro ;
Levine, Ross L. ;
Abdel-Wahab, Omar ;
Licht, Jonathan D. ;
Elemento, Olivier ;
Melnick, Ari M. .
CANCER CELL, 2013, 23 (05) :677-692
[3]   EZH2 mutations are frequent and represent an early event in follicular lymphoma [J].
Boedoer, Csaba ;
Grossmann, Vera ;
Popov, Nikolay ;
Okosun, Jessica ;
O'Riain, Ciaran ;
Tan, King ;
Marzec, Jacek ;
Araf, Shamzah ;
Wang, Jun ;
Lee, Abigail M. ;
Clear, Andrew ;
Montoto, Silvia ;
Matthews, Janet ;
Iqbal, Sameena ;
Rajnai, Hajnalka ;
Rosenwald, Andreas ;
Ott, German ;
Campo, Elias ;
Rimsza, Lisa M. ;
Smeland, Erlend B. ;
Chan, Wing C. ;
Braziel, Rita M. ;
Staudt, Louis M. ;
Wright, George ;
Lister, T. Andrew ;
Elemento, Olivier ;
Hills, Robert ;
Gribben, John G. ;
Chelala, Claude ;
Matolcsy, Andras ;
Kohlmann, Alexander ;
Haferlach, Torsten ;
Gascoyne, Randy D. ;
Fitzgibbon, Jude .
BLOOD, 2013, 122 (18) :3165-3168
[4]   The KDM5 family is required for activation of pro-proliferative cell cycle genes during adipocyte differentiation [J].
Brier, Ann-Sofie B. ;
Loft, Anne ;
Madsen, Jesper G. S. ;
Rosengren, Thomas ;
Nielsen, Ronni ;
Schmidt, Soren F. ;
Liu, Zongzhi ;
Yan, Qin ;
Gronemeyer, Hinrich ;
Mandrup, Susanne .
NUCLEIC ACIDS RESEARCH, 2017, 45 (04) :1743-1759
[5]   An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting [J].
Cao, Jian ;
Wu, Lizhen ;
Zhang, Shang-Min ;
Lu, Min ;
Cheung, William K. C. ;
Cai, Wesley ;
Gale, Molly ;
Xu, Qi ;
Yan, Qin .
NUCLEIC ACIDS RESEARCH, 2016, 44 (19)
[6]   Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells [J].
Casado, Pedro ;
Rodriguez-Prados, Juan-Carlos ;
Cosulich, Sabina C. ;
Guichard, Sylvie ;
Vanhaesebroeck, Bart ;
Joel, Simon ;
Cutillas, Pedro R. .
SCIENCE SIGNALING, 2013, 6 (268) :rs6
[7]   Dual-specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling [J].
Caunt, Christopher J. ;
Keyse, Stephen M. .
FEBS JOURNAL, 2013, 280 (02) :489-504
[8]  
Chapuy B, 2018, NAT MED, V15, P1
[9]   SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma [J].
Chen, Linfeng ;
Monti, Stefano ;
Juszczynski, Przemyslaw ;
Daley, John ;
Chen, Wen ;
Witzig, Thomas E. ;
Habermann, Thomas M. ;
Kutok, Jeffery L. ;
Shipp, Margaret A. .
BLOOD, 2008, 111 (04) :2230-2237
[10]   SYK Inhibition Modulates Distinct PI3K/AKT-Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas [J].
Chen, Linfeng ;
Monti, Stefano ;
Juszczynski, Przemyslaw ;
Ouyang, Jing ;
Chapuy, Bjoern ;
Neuberg, Donna ;
Doench, John G. ;
Bogusz, Agata M. ;
Habermann, Thomas M. ;
Dogan, Ahmet ;
Witzig, Thomas E. ;
Kutok, Jeffery L. ;
Rodig, Scott J. ;
Golub, Todd ;
Shipp, Margaret A. .
CANCER CELL, 2013, 23 (06) :826-838